Literature DB >> 10956398

Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study.

S Romain1, F Spyratos, F Descotes, A Daver, B Rostaing-Puissant, P Bougnoux, M Colonna, M Bolla, P M Martin.   

Abstract

Among the methodological approaches of tumor proliferation, thymidine kinase (TK) and thymidylate synthase (TS) assays take into account the specific pathways of pyrimidine synthesis. Studies pointing to a prognostic value of TK and TS in breast cancer involved small numbers of patients. We investigated the prognostic value of these enzymes and their combination in a large retrospective multicenter study. Nine hundred eight T1T2, N0N1, M0 primary breast cancer samples (median follow-up 68 months) were tested. TK and TS were measured in cytosols by using standardized radioenzymatic methods. Although a positive correlation was obtained between TK and TS (p<10(-5)), major discrepancies were observed in some tumors. High levels of both enzymes were associated with large tumor size, histological grade III and steroid receptor-negative tumors. Univariate analysis showed that TK, TS and their combination were predictive of poor metastasis-free (MFS) (p < 10(-4); p=0.004; p < 10(-4)) and disease-free survival (DFS) (p < 10(-4); p=0.007; p=0.0001). TK was selected as an independent factor for MFS in Cox analysis. It was the only variable selected in node-negative patients. Subgroups with specific outcomes, with possible therapeutic implications, were identified: a) in node-negative patients not receiving adjuvant treatment, TK values in the 4th quartile were associated with poor MFS (p=0.0002) and DFS (p=0.0005) as compared to the other quartiles; b) in node-positive patients receiving adjuvant chemotherapy, low levels of both TK and TS were associated with the highest survival rates (MFS: p=0.04; DFS: p=0. 03). Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10956398

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer.

Authors:  Osamu Nakahara; Hiroshi Takamori; Hiroshi Tanaka; Yasuo Sakamoto; Yoshiaki Ikuta; Satoshi Furuhashi; Masayuki Watanabe; Toru Beppu; Masahiko Hirota; Keiichiro Kanemitsu; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2010-02       Impact factor: 3.402

2.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

3.  Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.

Authors:  Kawai Yau; Patricia Price; Radhakrishma G Pillai; Eric Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

4.  Epstein-Barr virus as a marker of biological aggressiveness in breast cancer.

Authors:  C Mazouni; F Fina; S Romain; L Ouafik; P Bonnier; J-M Brandone; P-M Martin
Journal:  Br J Cancer       Date:  2010-12-21       Impact factor: 7.640

5.  Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival.

Authors:  S Desruisseau; J Palmari; C Giusti; S Romain; P-M Martin; Y Berthois
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

6.  Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.

Authors:  Kiran Kumar Jagarlamudi; Lars Olof Hansson; Staffan Eriksson
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

7.  Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

Authors:  Martina Bonechi; Francesca Galardi; Chiara Biagioni; Francesca De Luca; Mattias Bergqvist; Magnus Neumüller; Cristina Guarducci; Giulia Boccalini; Stefano Gabellini; Ilenia Migliaccio; Angelo Di Leo; Marta Pestrin; Luca Malorni
Journal:  Oncotarget       Date:  2018-03-27

Review 8.  Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice.

Authors:  Amelia McCartney; Ilenia Migliaccio; Martina Bonechi; Chiara Biagioni; Dario Romagnoli; Francesca De Luca; Francesca Galardi; Emanuela Risi; Irene De Santo; Matteo Benelli; Luca Malorni; Angelo Di Leo
Journal:  Front Oncol       Date:  2019-07-23       Impact factor: 6.244

9.  Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells.

Authors:  Lilibeth Lanceta; Conor O'Neill; Nadiia Lypova; Xiahong Li; Eric Rouchka; Sabine Waigel; Jorge G Gomez-Gutierrez; Jason Chesney; Yoannis Imbert-Fernandez
Journal:  Genes (Basel)       Date:  2020-04-24       Impact factor: 4.096

10.  Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.

Authors:  Luc Cabel; Dan Rosenblum; Florence Lerebours; Etienne Brain; Delphine Loirat; Mattias Bergqvist; Paul Cottu; Anne Donnadieu; Anne Bethune; Nicolas Kiavue; Manuel Rodrigues; Jean-Yves Pierga; Marie-Laure Tanguy; François-Clément Bidard
Journal:  Breast Cancer Res       Date:  2020-09-14       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.